Literature DB >> 24391200

Detection of Trichomonas vaginalis DNA by use of self-obtained vaginal swabs with the BD ProbeTec Qx assay on the BD Viper system.

Barbara Van Der Pol1, James A Williams, Stephanie N Taylor, Catherine L Cammarata, Charles A Rivers, Barbara A Body, Melinda Nye, Deanna Fuller, Jane R Schwebke, Mathilda Barnes, Charlotte A Gaydos.   

Abstract

Trichomonas vaginalis is the most prevalent nonviral sexually transmitted infection worldwide, and improved diagnostic methods are critical for controlling this pathogen. Diagnostic assays that can be used in conjunction with routine chlamydia/gonorrhea nucleic acid-based screening are likely to have the most impact on disease control. Here we describe the performance of the new BD T. vaginalis Qx (TVQ) amplified DNA assay, which can be performed on the automated BD Viper system. We focus on data from vaginal swab samples, since this is the specimen type routinely used for traditional trichomonas testing and the recommended specimen type for chlamydia/gonorrhea screening. Vaginal swabs were obtained from women attending sexually transmitted disease or family planning clinics at 7 sites. Patient-collected vaginal swabs were tested by the TVQ assay, and the Aptima T. vaginalis (ATV) assay was performed using clinician-collected vaginal swabs. Additional clinician-collected vaginal swabs were used for the wet mount and culture methods. Analyses included comparisons versus the patient infection status (PIS) defined by positive results with the wet mount method or culture, direct comparisons assessed with κ scores, and latent class analysis (LCA) as an unbiased estimator of test accuracy. Data from 838 women, 116 of whom were infected with T. vaginalis, were analyzed. The TVQ assay sensitivity and specificity estimates based on the PIS were 98.3% and 99.0%, respectively. The TVQ assay was similar to the ATV assay (κ=0.938) in direct analysis. LCA estimated the TVQ sensitivity and specificity as 98.3 and 99.6%, respectively. The TVQ assay performed well using self-collected vaginal swabs, the optimal sample type, as recommended by the CDC for chlamydia/gonorrhea screening among women.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24391200      PMCID: PMC3957762          DOI: 10.1128/JCM.02966-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Survival of Trichomonas vaginalis in wet preparation and on wet mount.

Authors:  Kevin A Stoner; Lorna K Rabe; Leslie A Meyn; Sharon L Hillier
Journal:  Sex Transm Infect       Date:  2013-04-20       Impact factor: 3.519

2.  Trichomonas vaginalis: in vitro attachment and internalization of HIV-1 and HIV-1-infected lymphocytes.

Authors:  José Rendón-Maldonado; Martha Espinosa-Cantellano; Carmen Soler; José V Torres; Adolfo Martínez-Palomo
Journal:  J Eukaryot Microbiol       Date:  2003 Jan-Feb       Impact factor: 3.346

3.  Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus.

Authors:  Prashini Moodley; David Wilkinson; Cathy Connolly; Jack Moodley; A Willem Sturm
Journal:  Clin Infect Dis       Date:  2002-01-07       Impact factor: 9.079

Review 4.  The clinical spectrum of Trichomonas vaginalis infection and challenges to management.

Authors:  Christina A Muzny; Jane R Schwebke
Journal:  Sex Transm Infect       Date:  2013-03-30       Impact factor: 3.519

5.  Trichomonas vaginalis genital infections: progress and challenges.

Authors:  Laura H Bachmann; Marcia M Hobbs; Arlene C Seña; Jack D Sobel; Jane R Schwebke; John N Krieger; R Scott McClelland; Kimberly A Workowski
Journal:  Clin Infect Dis       Date:  2011-12       Impact factor: 9.079

6.  Clinical evaluation of the BD ProbeTec™ Chlamydia trachomatis Qx amplified DNA assay on the BD Viper™ system with XTR™ technology.

Authors:  Stephanie N Taylor; Barbara Van Der Pol; Rebecca Lillis; Edward W Hook; William Lebar; Thomas Davis; Deanna Fuller; Leandro Mena; Paul Fine; Charlotte A Gaydos; David H Martin
Journal:  Sex Transm Dis       Date:  2011-07       Impact factor: 2.830

7.  'Shelf life' of Trichomonas vaginalis.

Authors:  M A Kingston; D Bansal; E M Carlin
Journal:  Int J STD AIDS       Date:  2003-01       Impact factor: 1.359

8.  Use of multiple nucleic acid amplification tests to define the infected-patient "gold standard" in clinical trials of new diagnostic tests for Chlamydia trachomatis infections.

Authors:  David H Martin; Malanda Nsuami; Julius Schachter; Edward W Hook; Dennis Ferrero; Thomas C Quinn; Charlotte Gaydos
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

Review 9.  Trichomoniasis and HIV interactions: a review.

Authors:  Patricia Kissinger; Alys Adamski
Journal:  Sex Transm Infect       Date:  2013-04-20       Impact factor: 3.519

10.  Treatment of Trichomonas in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda.

Authors:  Godfrey G Kigozi; Heena Brahmbhatt; Fred Wabwire-Mangen; Maria J Wawer; David Serwadda; Nelson Sewankambo; Ronald H Gray
Journal:  Am J Obstet Gynecol       Date:  2003-11       Impact factor: 8.661

View more
  18 in total

Review 1.  [Modern diagnosis of sexually transmitted diseases].

Authors:  N H Brockmeyer; T Meyer
Journal:  Hautarzt       Date:  2016-01       Impact factor: 0.751

2.  Trichomonas vaginalis Virus Among Women With Trichomoniasis and Associations With Demographics, Clinical Outcomes, and Metronidazole Resistance.

Authors:  Keonte J Graves; Arindam P Ghosh; Norine Schmidt; Peter Augostini; W Evan Secor; Jane R Schwebke; David H Martin; Patricia J Kissinger; Christina A Muzny
Journal:  Clin Infect Dis       Date:  2019-11-27       Impact factor: 9.079

3.  Clinical performance of the Solana® Point-of-Care Trichomonas Assay from clinician-collected vaginal swabs and urine specimens from symptomatic and asymptomatic women.

Authors:  C A Gaydos; J Schwebke; J Dombrowski; J Marrazzo; J Coleman; B Silver; M Barnes; L Crane; P Fine
Journal:  Expert Rev Mol Diagn       Date:  2017-01-29       Impact factor: 5.225

4.  Why Does Trichomonas vaginalis Continue to be a "Neglected" Sexually Transmitted Infection?

Authors:  Christina A Muzny
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

Review 5.  Strategies for Prevention and Treatment of Trichomonas vaginalis Infections.

Authors:  Kawthar Bouchemal; Christian Bories; Philippe M Loiseau
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

6.  Combined Testing for Chlamydia, Gonorrhea, and Trichomonas by Use of the BD Max CT/GC/TV Assay with Genitourinary Specimen Types.

Authors:  Barbara Van Der Pol; James A Williams; DeAnna Fuller; Stephanie N Taylor; Edward W Hook
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

7.  Incubation period and risk factors support sexual transmission of bacterial vaginosis in women who have sex with women.

Authors:  Christina Ann Muzny; Shelly Y Lensing; Kristal J Aaron; Jane R Schwebke
Journal:  Sex Transm Infect       Date:  2019-03-14       Impact factor: 3.519

8.  Optimal Timing for Trichomonas vaginalis Test of Cure Using Nucleic Acid Amplification Testing.

Authors:  Megan Clare Craig-Kuhn; Charleigh Granade; Christina A Muzny; Barbara Van Der Pol; Rebecca Lillis; Stephanie N Taylor; Norine Schmidt; David H Martin; Patricia Kissinger
Journal:  Sex Transm Dis       Date:  2019-05       Impact factor: 2.830

Review 9.  A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections.

Authors:  Elissa Meites; Charlotte A Gaydos; Marcia M Hobbs; Patricia Kissinger; Paul Nyirjesy; Jane R Schwebke; W Evan Secor; Jack D Sobel; Kimberly A Workowski
Journal:  Clin Infect Dis       Date:  2015-12-15       Impact factor: 9.079

10.  Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial.

Authors:  Patricia Kissinger; Christina A Muzny; Leandro A Mena; Rebecca A Lillis; Jane R Schwebke; Laura Beauchamps; Stephanie N Taylor; Norine Schmidt; Leann Myers; Peter Augostini; William E Secor; Martina Bradic; Jane M Carlton; David H Martin
Journal:  Lancet Infect Dis       Date:  2018-10-05       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.